The Medical Letter - 2021
Search or Select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Year:    Publication:     
March 8, 2021 (Issue 1619)  
February 22, 2021 (Issue 1618)  
February 8, 2021 (Issue 1617)  
  • Twirla - A New Contraceptive Patch   
    The FDA has approved Twirla (Agile Therapeutics), a transdermal contraceptive patch containing the estrogen ethinyl estradiol and the progestin levonorgestrel, for use in women with a BMI
  • Pitolisant (Wakix) for Narcolepsy   
    The FDA has approved pitolisant (Wakix – Harmony), a histamine-3 (H3)-receptor antagonist/inverse agonist, for treatment of excessive daytime sleepiness (EDS) or cataplexy in...
  • Osilodrostat (Isturisa) for Cushing's Disease   
    The FDA has approved osilodrostat (Isturisa – Recordati), a cortisol synthesis inhibitor, for oral treatment of adults with Cushing's disease when surgical resection of the pituitary...
  • Avapritinib (Ayvakit) for GIST   
    The FDA has approved the oral tyrosine kinase inhibitor avapritinib (Ayvakit – Blueprint Medicines) for treatment of unresectable or metastatic gastrointestinal stromal tumors (GISTs)...
January 25, 2021 (Issue 1616)  
January 11, 2021 (Issue 1615)